Amiodarone-induced Lung Toxicity. In Vitro Evidence for the Direct Toxicity of the Drug

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1985 Sep 1

PMID 2994482

Citations 8

Authors

W J Martin

D M Howard

Affiliations

Soon will be listed here.

Abstract

Amiodarone, a new antiarrhythmic agent, is associated with serious lung toxicity. This study indicates that in vitro amiodarone can directly induce bovine pulmonary artery endothelial cells to form cytoplasmic lamellar inclusions characteristic of the lung biopsy findings described in vivo. These morphologic changes occur as soon as 4 hours after incubation with the drug and with as little as 1 microgram/ml (within the therapeutic range). Amiodarone-induced endothelial cell injury, monitored by 51Cr release, occurs with as little as 10-20 micrograms/ml. The data suggest that amiodarone toxicity to the lung may be primarily related to its direct toxic effect on lung cells, and that the characteristic morphologic changes of cytoplasmic inclusions may represent an early sign of the drug's effect.

Citing Articles

Artemisinin protected human bronchial epithelial cells from amiodarone-induced oxidative damage via 5'-AMP-activated protein kinase (AMPK) activation.

Yang C, Xiong W, Dong J, Zhao X, Liang G, Zheng W Redox Rep. 2025; 30(1):2447721.

PMID: 39803706 PMC: 11731350. DOI: 10.1080/13510002.2024.2447721.

A Case of Amiodarone Pulmonary Toxicity with Short-term Amiodarone Use.

McDonald A Cureus. 2020; 12(4):e7680.

PMID: 32426192 PMC: 7228794. DOI: 10.7759/cureus.7680.

Cytotoxicity of amiodarone in cultured human endothelial cells.

Baudin B, Beneteau-Burnat B, Giboudeau J Cardiovasc Drugs Ther. 1996; 10(5):557-60.

PMID: 8950070 DOI: 10.1007/BF00050996.

Susceptibility to amiodarone-induced pulmonary toxicity: relationship to the uptake of amiodarone by isolated lung cells.

Wilson B, Lippmann M Lung. 1996; 174(1):31-41.

PMID: 8747000 DOI: 10.1007/BF00167949.

Amiodarone--induced changes in surfactant phospholipids of rat lung.

Padmavathy B, Devaraj H, Devaraj N Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(4):421-4.

PMID: 8510769 DOI: 10.1007/BF00165393.

References

Lazarus S, Vethamany V, Schneck L, VOLK B . Fine structure and histochemistry of peripheral blood cells in Niemann-Pick disease. Lab Invest. 1967; 17(2):155-70. View

Martin 2nd W, Powis G, Kachel D . Nitrofurantoin-stimulated oxidant production in pulmonary endothelial cells. J Lab Clin Med. 1985; 105(1):23-9. View

Askin F, Kuhn C . The cellular origin of pulmonary surfactant. Lab Invest. 1971; 25(3):260-8. View

HRUBAN Z, SLESERS A, Aschenbrenner I . Pulmonary intra-alveolar histiocytosis induced by drugs. Toxicol Appl Pharmacol. 1973; 26(1):72-85. DOI: 10.1016/0041-008x(73)90087-2. View

Delage C, Lagace R, Huard J . Pseudocyanotic pigmentation of the skin induced by amiodarone: a light and electron microscopic study. Can Med Assoc J. 1975; 112(10):1205-8. PMC: 1959100. View

LULLMANN H, Lullmann-Rauch R, Wassermann O . Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol. 1975; 4(2):185-218. DOI: 10.1080/10408447509164014. View

Gaton E, Wolman M . Histochemical study on the pathogenesis of chlorocyclizine-induced pulmonary lipidosis. Histochemistry. 1979; 63(2):203-7. DOI: 10.1007/BF00644542. View

DAmico D, Kenyon K, Ruskin J . Amiodarone keratopathy: drug-induced lipid storage disease. Arch Ophthalmol. 1981; 99(2):257-61. DOI: 10.1001/archopht.1981.03930010259007. View

MARCUS F, Fontaine G, Frank R, Grosgogeat Y . Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone. Am Heart J. 1981; 101(4):480-93. DOI: 10.1016/0002-8703(81)90140-x. View

10.

Heger J, Prystowsky E, Jackman W, Naccarelli G, Warfel K, Rinkenberger R . Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981; 305(10):539-45. DOI: 10.1056/NEJM198109033051002. View

11.

Andreasen F, Agerbaek H, Bjerregaard P, GOTZSCHE H . Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol. 1981; 19(4):293-9. DOI: 10.1007/BF00562807. View

12.

Sobol S, RAKITA L . Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation. 1982; 65(4):819-24. DOI: 10.1161/01.cir.65.4.819. View

13.

Manhem P, PAALZOW L, HOKFELT B . Plasma clonidine in relation to blood pressure, catecholamines, and renin activity during long-term treatment of hypertension. Clin Pharmacol Ther. 1982; 31(4):445-51. DOI: 10.1038/clpt.1982.58. View

14.

Riva E, Gerna M, Neyroz P, Urso R, BARTOSEK I, Guaitani A . Pharmacokinetics of amiodarone in rats. J Cardiovasc Pharmacol. 1982; 4(2):270-5. DOI: 10.1097/00005344-198203000-00016. View

15.

Marchlinski F, Gansler T, Waxman H, Josephson M . Amiodarone pulmonary toxicity. Ann Intern Med. 1982; 97(6):839-45. DOI: 10.7326/0003-4819-97-6-839. View

16.

Canada A, Lesko L, Haffajee C, Johnson B, Asdourian G . Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. Drug Intell Clin Pharm. 1983; 17(2):100-4. DOI: 10.1177/106002808301700203. View

17.

Gefter W, Epstein D, Pietra G, Miller W . Lung disease caused by amiodarone, a new antiarrythmic agent. Radiology. 1983; 147(2):339-44. DOI: 10.1148/radiology.147.2.6836114. View

18.

RAKITA L, Sobol S, Mostow N, VROBEL T . Amiodarone pulmonary toxicity. Am Heart J. 1983; 106(4 Pt 2):906-16. DOI: 10.1016/0002-8703(83)90015-7. View

19.

Heger J, Prystowsky E, Zipes D . Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J. 1983; 106(4 Pt 2):931-5. DOI: 10.1016/0002-8703(83)90018-2. View

20.

Morady F, Sauve M, Malone P, Shen E, Schwartz A, Bhandari A . Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol. 1983; 52(8):975-9. DOI: 10.1016/0002-9149(83)90515-5. View